Abstract. Gene therapy is a promising therapeutic option for the treatment of various cancers, and tumor-targeted plasmids encoding toxic protein genes are potential tools for gene therapy. In the present study, a recombinant plasmid containing the genes for the toxic protein melittin and interleukin-2 (IL-2) was constructed. Melittin and IL-2 are known to play key roles in immunoregulation and cancer therapy, but they each possess defects that limit the clinical application of these proteins. The present study aimed to construct a novel recombinant expression plasmid, pLEGFP-C1-M-IL-2( 
Ala), and to improve the biological activity of IL-2 and melittin. The M-IL-2(
88 Arg, 125 Ala) gene was excised from the pPICZαA/M-IL-2( 88 Arg, 125 Ala) plasmid by polymerase chain reaction (PCR). The pLEGFP-C1 plasmid carrying the enhanced green fluorescent protein (EGFP) gene was used as a shuttle plasmid. Subsequent to digestion, the M-IL-2( 88 Arg, 125 Ala) gene was subcloned into the pLEGFP-C1 vector to build the pLEGFP-C1-M-IL-2( 88 Arg, 125 Ala) eukaryotic expression plasmid, which was identified by restriction enzyme digestion and gene sequencing. Confocal microscopy was used to determine the transfection efficiency subsequent to the plasmid being transfected into the cervical cancer HeLa cell line. The cells transfected with the pLEGFP-C1-M-IL-2( 88 Arg, 125 Ala) plasmid demonstrated a decreased transfection efficiency compared with the cells transfected with the pLEGFP-C1 plasmid.
The cellular expression of M-IL-2(
88 Arg, 125 Ala) was detected by reverse transcription PCR and western blot analysis. Finally, cell counting kit-8 and apoptosis assays were performed to investigate the effects of the expression of the M-IL-2( 125 Ala) fusion protein was able to inhibit HeLa cell proliferation and induce apoptosis in the tumor cells. These findings may offer an alternative method for anticancer therapy. The present study has provided a basis for future studies into the M-IL-2(
Introduction
Melittin is a naturally-occurring cytolytic antimicrobial peptide that consists of 26 amino acids, with a molecular weight of 2846.46, and constitutes 40-50% of dry whole honeybee venom (1) (2) (3) (4) . Melittin has been proposed as a possible anticancer drugs with high potential and the antibacterial, antiviral, anti-inflammatory and anticancer properties demonstrated by the protein have been previously described (1) (2) (3) (4) . Numerous studies have reported several mechanisms of melittin cytotoxicity in various types of cancer cells, with mechanisms including growth inhibition, induction of apoptosis, cell cycle alterations and an effect on proliferation (5, 6) . The melittin peptide possesses numerous biological properties, but the hemolytic action of the melittin peptide limits the clinical applications of the protein (2).
Human interleukin-2 (hIL-2) acts as a T cell growth factor and plays a key role in the generation of antitumor immunity mediated by cytotoxic T lymphocytes. IL-2 is able to influence several types of cancer effectively, including renal cell carcinoma, melanoma and liver cancer (7) (8) (9) . In addition, recombination of the IL-2 gene has been clinically used as a type of drug to treat a variety of tumors (10, 11) . Despite the functions of IL-2, the toxicity and short half-life of IL-2 also limit the clinical application of this protein (7) . Therefore, numerous studies worldwide have investigated mutant recombinant hIL-2 to increase the biological activity of the protein and to minimize the corresponding systemic toxicity (12) (13) (14) . In the present study, the IL-2 gene was modified by site-specific mutagenesis procedures into IL-2( 88 Arg, 125 Ala). An associated study has indicted that mutant hIL-2, which possesses an asparagine to arginine substitution at residue 88, is more selective for T cells than NK cells compared with the wild-type hIL-2 in vitro (12 Ala) fusion protein may be a potential agent for cancer therapy, and is therefore important for future studies. 
Materials and methods

Materials
Construction of the pLEGFP-C1-M-IL-2(
88 Arg, 125 Ala) plasmid ( Fig. 1 125 Ala) plasmid by polymerase chain reaction (PCR) using the p1 and p2 primers (Table I) , which added HindIII and BamHI restriction sites to the 5' and 3' ends of the gene, respectively. The parameters for PCR were as follows: Pre-denaturation at 94˚C for 4 min, denaturation at 94˚C for 45 sec; annealing at 56˚C for 30 sec; extension at 72˚C for 30 sec; and further extension at 72˚C for 10 min. This protocol was performed for 30 cycles. The pPICZαA/M-IL-2( 88 Arg, 125 Ala) plasmid was identified by restriction analysis, which was performed using the EcoRI and KpnI enzymes, and the plasmid was sequenced using p3 and p4 primers (Table I) Ala) was then subcloned into the pLEGFP-C1 plasmid using T4 DNA ligase, forming the recombinant plasmid pLEGFP-C1-M-IL-2( 88 Arg, 125 Ala). This plasmid was transformed into competent E. coli DH5α cells and the cells were selected on solid Luria-Bertani broth plates containing 10.0 g/l tryptone, 10.0 g/l NaCl, 5.0 g/l yeast extract and 15.0 g/l agar (pH 7.2-7.5), in addition to 100 µg/ml ampicillin. The recombinant plasmid was amplified in positive transformants and extracted using the plasmid extraction kit. The plasmid was then identified by restriction analysis using BamHI and HindIII, PCR and sequencing with the p5 and p6 primers (Table I) Ala) plasmid groups. The transfection was performed according to the instructions provided by the manufacturer of the Lipofectamine 2000 when the cell confluence reached 90%. Transfection efficiency was measured 24 h subsequent to transfection using an Olympus confocal microscope (Olympus, Tokyo, Japan), and the cells were subjected to the subsequent assays.
Detection of M-IL-2( 88 Arg, 125 Ala) mRNA expression by RT-PCR. Total RNA was extracted from HeLa cells using TRIzol reagent. First-strand cDNA was synthesized using the RevertAid First Strand cDNA Synthesis kit. RT-PCR was then conducted according to the manufacturer's instructions, using the first-strand cDNA as a template and the primers p1, p2, p7 and p8 (Table I) . In each reaction, GAPDH was used as an internal control. The parameters for PCR were as follows: Pre-denaturation at 94˚C for 4 min; denaturation at 94˚C for 45 sec; annealing at 56˚C for 30 sec; extension at 72˚C for 30 sec; and further extension at 72˚C for 10 min. This PCR protocol was performed for 30 cycles. The resulting PCR products were analyzed with a Vilber Lourmat imaging system (Quantum ST4, Vilber Lourmat Deutschland GmbH, Eberhardzell, Germany).
Western blot analysis. The cells on the bottom surface of the culture plate and in the medium were harvested at 48 h subsequent to transfection. Total protein was extracted using radio immunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, Jiangsu, China) and the concentration of the protein was identified using the bicinchoninic acid protein assay kit (Beijing ComWin Biotech Co., Ltd., Beijing, China). Various samples containing the same amount of protein were loaded on a 12% SDS-PAGE gel and the gel was wet-transferred onto polyvinylidene fluoride membranes (Virostat, Inc., Westbrook, ME, USA). The membranes were blocked using Tris-buffered saline with Tween 20 (Cell Signaling Technology, Inc., Danvers, MA, USA) containing 5% skim milk for 2 h and then incubated with polyclonal rabbit anti-human hIL-2 (1:250; cat. no. bs-0605R, Bioss, Inc., Woburn, MA, USA) and rabbit anti-human GAPDH antibodies (1:10,000; cat. no. bs-2188R, Bioss, Inc.) at 4˚C overnight, followed by incubation with the secondary horseradish peroxidase-conjugated polyclonal goat anti-rabbit antibody (1:10,000; cat. no. ASS1009, Bioss, Inc.) at room temperature for 2 h. The results were detected using the Vilber Lourmat imaging system.
The anti-tumor effects of the M-IL-2(
88 Arg, 125 Reagent. The experimental data were acquired using a Guava Mini flow cytometer (EMD Millipore, Billerica, MA, USA).
Statistical analysis. All data are expressed as the mean ± standard deviation. Statistical comparisons between groups were analyzed using one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.
Results
Identification of the pPICZαA/M-IL-2(
88 Arg, 
Construction of the pLEGFP-C1-M-IL-2(
88 Arg, 125 Ala) plasmid.
The purified PCR products of M-IL-2(
88 Arg, 125 Ala) were inserted into the backbone of the pLEGFP-C1 plasmid subsequent to digestions by BamHI and HindIII (Fig. 2B and C) . Subsequent to transformation, the positive transformants were selected on SLB plates containing 100 µg/ml ampicillin. The 726-bp products of PCR performed on pLEGFP-C1-M-IL-2( 88 Arg, 125 Ala) with primers p5 and p6 and restriction analysis with BamHI and HindIII ( Fig. 2D and E) Ala) fusion protein compared with the cells transfected with the empty pLEGFP-C1 plasmid and the non-transfected cells (Fig. 3A-C) . 
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protein on HeLa cells was detected by the CCK-8 and apoptosis assays. The morphology of the cells was observed at 24, 48 and 72 h (Fig. 4) and the CCK-8 assay was performed at 24, 48 and 72 h subsequent to transfection (Fig. 5) . The apoptosis assay was performed at 72 h post-transfection (Fig. 6) .
The results indicted that the cells in the group transfected with the pLEGFP-C1-M-IL-2( 88 Arg, 125 Ala) plasmid grew at a slower rate compared with the control groups. It was therefore indicated that the overexpression of the fusion protein inhibited the proliferation of HeLa cells and induced apoptosis.
Discussion
Tumor-targeted plasmids encoding toxic protein genes are reliable tools in gene therapy that are able to be used in various tumors (18, 19) . In the present study, a novel recombinant eukaryotic expression plasmid, which contained the genes for a toxic fusion protein that was comprised of melittin and IL-2( 88 Arg, 125 Ala), was constructed initially and the plasmid was then successfully transfected into HeLa cells.
The hIL-2 protein acts as a T cell growth factor and plays a key role in the generation of the antitumor immunity that is (20) . IL-2 was also one of the first cytokines used for gene therapy and was found to possess a wide range of target immune cells. The administration of IL-2 has been recognized as a useful tool in immunotherapy for various tumors, including melanoma, prostate cancer and neuroblastoma (1, 21) , but a short half-life and resulting systemic toxicity limit the application of this protein.
Melittin is a naturally-occurring cytolytic antimicrobial peptide that possesses numerous biological functions. The protein has been used as a traditional medicine to treat back pain, rheumatism and skin diseases due to antibacterial, antiviral and anti-inflammatory effects, and certain studies have demonstrated the antitumor activity of melittin (22, 23) . Despite these properties, melittin also demonstrates several defects.
In the present study, the IL-2 gene sequence was modified and the fusion gene M-IL-2( 
